Prosigna® is a genetic test based on the genetic signature PAM50, which evaluates the expression or activity of 50 key genes in tumor tissue; allowing to estimate the risk of disease recurrence, and the intrinsic biological subtype specific to each patient.
The result of the Prosigna test, interpreted in conjunction with other factors, is a prognostic indicator for patients and allows the oncologist to choose the optimal treatment. The doctor can make a more informed and personalized decision about the need to undergo chemotherapy.
The only genomic diagnostic test that identifies the Intrinsic Subtype of Breast Cancer.
It gives a risk classification, with a recurrence risk score in a 100-point scale, offers a greater range of personalized prognostic information that is highly valuable for making decisions about the treatment for each patient.
Scientifically validated in different trials with more than 4000 patients in total.
Results are ready in just 10 business days.
The expression of 50 key genes is measured from a tumor sample extracted during surgery. No additional intervention is necessary. This information is analyzed by the Prosigna algorithm in conjunction with other variables such as tumor size and lymph node status to offer the results report which is sent directly to the Oncologist.
The results offered by Prosigna are 4: the ROR or risk of recurrence, the intrinsic subtype, the risk classification and the probability of recurrence at a distance of 10 years.
ROR: Recurrence risk or ROR; It is a scale index from 0 to 100, it is based on the genetic information of the tumor; combined with its size and intrinsic subtype. A lower ROR corresponds to a lower risk of cancer recurrence for that specific patient, as well as a lower probability of benefit from chemotherapy.
Intrinsic subtype: according to the genetic analysis of the affected tissue, the type of cancer is classified into the 4 possible subtypes. It provides crucial information to offer the patient a personalized treatment.
Risk classification: According to the ROR obtained and the number of affected nodes, it can be classified as low, intermediate and high.
Distant recurrence: it is a percentage that is calculated by combining the genetic estimators (ROR) and intrinsic subtype obtained from the history of more than 2400 patients; It consists of the percentage of patients with the same lymph node situation with recurrence in a period of 10 years.
Your doctor may use the information offered by Prosigna to choose appropriate treatment.
You should talk with your treating doctor about the Prosigna test, and your treating doctor must make the request with Oncogenomics to perform the test.
The test is performed on the surgically extracted tumor sample, and the results take 10 business days to be sent to the prescribing physician.
After surgery, where the surgeon has removed the tumor tissue, it will be examined and prepared by the pathologist. Once the Oncologist has decided to perform the test, Oncogenomics collects the sample and delivers it to the analysis laboratory. The results are subsequently sent to the doctor in order to make a personalized decision about the most appropriate treatment for the patient.
To learn more about Nanostring Technologies, the manufacturer of the Prosigna test, you can visit the following address: https://www.nanostring.com/
To learn more about Oncogenomics you can visit https://www.oncogenomics.es/en/about
For any additional questions you can contact us through the following address: https://www.oncogenomics.es/en/contact/